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Abstract
Background: Up to 75% of inpatients with mental disorders smoke, and their life expectancy is decreased by up to
25 years compared to the general population. Hospitalized patients without monitoring after discharge quickly return
to prehospitalization levels of tobacco use. The aim of the 061 QuitMental study is to assess the effectiveness of a
multicomponent and motivational telephone-based intervention to stop smoking through a quitline addressed to
smokers discharged from mental health hospital wards.
Methods: A pragmatic randomized controlled trial, single blinded, will include 2:1 allocation to the intervention group
(IG) and the control group (CG). The IG will receive telephone assistance to quit smoking (including psychological and
psychoeducational support, and pharmacological treatment advice if required) proactively for 12months, and the CG
will receive only brief advice after discharge. The sample size, calculated with an expected difference of 15 points on
smoking abstinence between groups (IG, 20% and CG, 5%), α = 0.05, β = 0.10, and 20% loss, will be 334 participants (IG)
and 176 participants (CG). Participants are adult smokers discharged from psychiatric units of five acute hospitals.
Measurements include dependent variables (self-reported 7-day point prevalence smoking abstinence (carbon monoxide
verified), duration of abstinence, number of quit attempts, motivation, and self-efficacy to quit) and independent variables
(age, sex, and psychiatric diagnoses). In data analysis, IG and CG data will be compared at 48 h and 1, 6, and 12months
post discharge. Multivariate logistic regression (odds ratio; 95% confidence interval) of dependent variables adjusted for
potential confounding variables will be performed. The number needed to treat to achieve one abstinence outcome will
be calculated. We will compare the abstinence rate of enrolled patients between groups.
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Discussion: This trial evaluates an innovative format of a quitline for smokers with severe mental disorders regardless of
their motivation to quit. If effective, the pragmatic nature of the study will permit transfer to routine clinical practice in the
National Health System.
Trial registration: ClinicalTrials.gov, NCT03230955. Registered on 24 July 2017.
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Key points
 This study is the first designed specifically for
mental health patients with a long-term follow-up of
1 year, as other studies have performed follow-up
periods of 6–7 months maximum.
 This trial evaluates an innovative quitline for
smokers with severe mental disorders regardless of
their motivation to quit.
 If effective, the pragmatic nature of the study will
permit transfer to routine clinical practice in the
National Health System.
Background
Smoking prevalence has declined over the last decade in
developed countries. However, in some vulnerable popu-
lations, such as people suffering from mental disorders,
the prevalence has not followed this trend [1–3]. People
with mental disorders are more likely to smoke, and the
greater number of lifetime psychiatric diagnoses, the
greater the probability of smoking [4]. In Catalonia,
74.4% of patients hospitalized for mental disorders
smoke [5], which is three times higher than the smoking
rate (26.9%) in the general population [6]. In addition,
these patients start to smoke at an early age, experience
higher levels of nicotine dependence, and have more
difficulty quitting [7, 8].
The reasons for higher consumption of tobacco among
people with mental disorders are not clear. Several expla-
nations have been suggested, including genetic factors or/
and a low socioeconomic level [9]. Another explanation
sometimes invoked is the self-medication hypothesis,
which suggests that patients with mental disorders, and
particularly those with schizophrenic diagnoses, smoke to
ameliorate their symptoms. However, this hypothesis is in-
creasingly rejected [10, 11].
Tobacco is the cause of death for 48–53% of people
with mental illness [12, 13] primarily for cardiovascular
and respiratory diseases, cancer, and diabetes [14]. For
people with severe mental illness, life expectancy is
reduced up to 10–17 years, mainly for illnesses caused
or worsened by smoking [15–17]. The persistent high
prevalence of tobacco use within this population high-
lights how public health and healthcare services have
neglected the needs of this disadvantaged population
[18]. Historically, tobacco consumption has been considered
a “minor problem” among patients with mental disorders; it
was believed that these patients were not interested in quit-
ting [19] and even that smoking helped patients control
their disorder [20]. Some of these beliefs may be reflected in
smoking cessation research. While there have been approxi-
mately 9000 smoking cessation trials among general popula-
tion smokers, there have been only 20 such trials among
patients with mental disorders [21]. The few studies that
have been done, however, indicate that patients with mental
disorders can achieve significant rates of abstinence [20].
Over the last decade, some jurisdictions have imple-
mented cost-effective measures, as proposed by the
World Health Organization (WHO), to curb smoking
among persons with mental disorders [20]. These mea-
sures are mainly policies for smoke-free areas, treatment
to quit smoking, and community measures of sustained
support to quit [22].
Hospitalization in smoke-free psychiatric centers in-
creases the quality of life in both patients and professionals,
and decreases the exposure to second-hand smoke [23]. In
addition, such policies increase quit attempts by patients
and their expectations of staying abstinent [24, 25]. Only
total smoke-free areas completely protect patients from
second-hand smoke [26]. In Spain, the tobacco control Law
42/2010 bans smoking in both indoors and outdoors areas
of acute hospitals including psychiatric units. This legal
framework, which implies abstinence of patients during
hospitalization, creates a unique opportunity to promote
smoking cessation among patients with mental disorders.
Concerning treatment to quit smoking, the use of
self-help materials, telephone advice, and psychological and
pharmacological treatments have been shown to be effec-
tive [27, 28]. Although interventions to promote smoking
cessation among patients with mental disorders aim to
achieve abstinence, it is often necessary to first promote
motivation to quit [27]. Thus, these patients would be able
to make serious attempts to quit smoking when hospitals
have trained professionals to respond to their needs and
offer them pharmacological and psychological aids [29]. In-
terventions that combine pharmacological treatment and
psychological therapy—primarily cognitive-behavioral psy-
chological treatment—increase the likelihood of tobacco
cessation in patients with mental disorders [30–32]. How-
ever, without patient monitoring after discharge, smoking is
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restored to previous levels in 2 weeks [33, 34]. Only a few
clinical trials [21, 35, 36] have demonstrated the efficacy of
multicomponent interventions (which included motiv-
ational, psychosocial, and pharmacological components)
addressed to patients with mental disorders after discharge.
In these studies, the intervention group showed higher ab-
stinence rates, more quit attempts, and fewer cigarettes per
day as compared to controls [21, 35, 36]. In addition, as
shown in the general population, it is likely that patients
with a mental disorder who quit smoking also reduce their
levels of anxiety, increase their quality of life, and obtain
better results in abstinence from other drugs [37].
In relation to community measures, “quitlines” (i.e.,
telephone counseling) stand out as an effective support
in the general population [38]. However, this resource
has so far been little used among populations with men-
tal disorders [39]. The few studies conducted with men-
tally ill patients showed that a quitline intervention
combined with nicotine replacement therapy (NRT)
slightly but significantly increased 7-day point preva-
lence abstinence at 6 months follow-up, reduced the
number of cigarettes consumed per day, and increased
readiness to quit smoking [36, 39].
In Catalonia, the health information and care telephone
line “061 CatSalut Respon” provides a free support program
to quit smoking, which acts as a quitline. A nursing team,
experts in telephone assistance and smoking cessation, pro-
vide an individualized intervention to quit smoking through
intensive care for 1 year. However, this service has not so
far been used for patients with mental disorders. Quitlines
may have some advantages over other cessation services, as
they can increase access, are less costly than face-to-face
visits [38], and offer a solution to the lack of systematic in-
terventions in patients with mental disorders especially
after discharge [34, 40]. However, contact with the quitline
is usually initiated by the smoker, and is not usually
initiated proactively by the treatment provider. Therefore,
we propose a pragmatic randomized controlled trial that
uses the existing resources of 061 CatSalut Respon to
engage patients with mental disorders identified during
hospitalization in acute psychiatric hospital units.
The aim of this study is to assess the effectiveness
of a telephone-based (quitline) intervention for smo-
king cessation addressed to smokers with severe men-
tal disorders after discharge from adult inpatient
acute units (the 061 QuitMental study). The interven-
tion group (IG) will receive a telephone intervention
to quit smoking (including psychological and psychoe-
ducational support and pharmacological treatment ad-
vice, if required) proactively for 12 months, and the
control group (CG) will receive only brief counseling
after discharge.
The specific objectives of the 061 QuitMental study
are as follows:
a. to assess the effectiveness of the intervention in
relation to the characteristics of the smokers
(mental disorder, comorbidity, age, sex, and
educational level and occupation);
b. to compare the levels of motivation to quit
smoking, self-efficacy, attempts to quit smoking,
and the likelihood of smoking abstinence in the
intervention group and the control group;
c. to describe the use and satisfaction with the quitline
in the intervention group and the control group; and
d. to assess the feasibility of this intervention to
systematically offer it at a community level.
These objectives will be analyzed by comparing the re-
sults obtained from the IG and the CG at several time
points post discharge: 48 h and 1, 6, and 12months (Fig. 1).
The hypotheses of this study are the following:
a. IG participants, as compared to CG participants,
will demonstrate higher rates of biochemically
verified 7-day point prevalence smoking abstinence,
at all evaluation time points (48 h and 1, 6, and 12
months post discharge).
b. IG participants, as compared to CG participants,
will experience longer periods of sustained
abstinence as demonstrated by sequential
biochemically verified 7-day point prevalence smok-
ing abstinence, at all evaluation time points.
c. IG participants who continue to smoke, as
compared to CG participants, will show greater
reduction in the number of cigarettes smoked per
day, at all evaluation time points.
d. IG participants who continue to smoke, as
compared to CG participants, will show an increase
in the progression of their readiness to quit
smoking, based on stages of change, at all
evaluation time points.
e. IG participants, as compared to CG participants,
will have a higher level of self-efficacy to quit at all
evaluation time points.
Methods
This project arises from the collaboration between the
Catalan Institute of Oncology, the Public Health Agency of
Catalonia, and the 061 CatSalut Respon program, which is
a public telephone service from the National Health System
about health topics addressed to all citizens.
Design
This study is a pragmatic randomized controlled trial
(RCT) with two groups: intervention group (n = 334) and
control group (n = 176). The subjects will be followed up
to 12months. The duration of the study is 3 years and is
divided into three phases: phase I, intervention design and
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pilot study for 1month; phase II, recruitment during 24
months; and phase III, analyses of the effectiveness of the
intervention, publication of the results, and dissemination
(6months after phase II).
Study population
The study population includes smokers with mental dis-
orders admitted to the mental health wards of five acute
care hospitals of Barcelona (Hospital Clinic i Provincial
de Barcelona, Hospital de la Santa Creu i Sant Pau,
Hospital Universitari Vall d’Hebron, Hospital Universitari
de Bellvitge, and Hospital Hestia Duran i Reynals). The in-
clusion criteria are: patients who consider themselves
smokers, both daily and occasional smokers (less than 1
cigarette per day); adults of both sexes aged 18–76 years;
patients who have stayed in an acute or detoxification
Fig. 1 Study variables and collection time points. GHQ-12 12-item version of the General Health Questionnaire
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mental health unit for more than 24 h; patients with a
telephone, fixed or mobile; residents in the metropolitan
area of Barcelona; and patients who provide informed
consent. The exclusion criteria are: patients discharged
from the psychiatric emergency rooms; patients with de-
mentia or brain damage; patients who do not speak or
read Spanish or Catalan; pregnant women; patients with
hearing and/or speech deficit; patients who are trying to
quit smoking in another center or using another interven-
tion; patients who have voluntarily requested discharge;
patients who are discharged to another inpatient unit; and
patients who plan to move their household outside the
Barcelona metropolitan area within the next 24months.
Clinical professionals (coordinated by a researcher
from each hospital) will evaluate whether patients met
the inclusion/exclusion criteria.
Sample size and randomization
Data from the five centers indicate that each year 1744
patients are admitted to their acute and detoxification
mental health units, of which 70% are expected to be
smokers [5]. Setting a risk of α = 0.05 and β = 0.10, and
with 2:1 randomization, 334 subjects are required in the
IG arm and 167 in the CG arm to detect a statistically
significant difference of 15 percentage points between
the proportion of abstinence in both groups (IG abstin-
ence rate, 20% and CG abstinence rate, 5%) after 12
months, with an estimated 20% loss to follow-up. Hence,
participants will be randomized into the IG and the CG
with 2:1 allocation using mapping software. The main
reason for the unequal allocation (2 IG:1 CG) was eth-
ical, in order to maximize the number of participants in-
cluded in the treatment group, as the treatment is
supposed to be beneficial for them.
Variables
Outcome measures
Primary outcome measure Self-reported 7-day point
prevalence smoking abstinence, biochemically verified
with expired carbon monoxide (CO) measures, is the
primary outcome. Seven days of abstinence has been
chosen as a consumption measure [41]. This variable
will be recorded in every call of the intervention (48 h, 1
week, 15 days, and 1, 3, 6, and 12months post
discharge). Abstinent subjects at 1, 6, and 12 months
in either of both groups (IG or CG) will be invited to
attend a consultation at their hospital to verify their
abstinence through the detection of exhaled carbon
monoxide. The abstinence rate between the IG and
the CG will be compared at 1, 6, and 12 months. In
each call, nicotine withdrawal symptoms will be
assessed according to the scale proposed by Hughes
and Hatsukami [42].
Secondary outcome measure We will also record other
smoking variables such as continuous abstinence. More-
over, for nonabstinent patients we will ask about their
tobacco use (quantity), type of tobacco consumed
(cigarette/cigar/other), number of quit attempts, and
other variables included in the “smoking” section in
Fig. 1. Moreover, using an ad-hoc Likert scale from 0 to
10 we will evaluate the level of self-efficacy to quit or re-
duce consumption, the intention to quit, and the
intention to reduce consumption. The individual’s will-
ingness to quit will be also evaluated according to the
Prochaska and Di Clemente Stages of Change model,
which measures four stages of readiness to quit smoking
(precontemplation, contemplation, action, and main-
tenance) [43].
Independent variables
Using a data collection form we will collect the following
information:
a) Sociodemographic data such as sex, age,
occupation, and highest level of education attained.
b) History and pattern of tobacco use, which will
include information to obtain the Heavy Smoking
Index as a measure of nicotine dependence self-
reported by the participants [44, 45].
c) General health data, such as self-perceived general
health assessment by the question “how would you
describe your health in a general way?”, and other
medical conditions.
d) Mental health data, such as diagnoses according to
the DSM-5 groups of diagnostic criteria [46] and
psychotropic treatment, will be obtained from par-
ticipants’ clinical records by the researchers,
whereas information about the number of emer-
gency room visits, readmissions to psychiatric
wards, and evaluation of mental distress measured
using the 12-item version of the General Health
Questionnaire (GHQ-12) [47, 48] will be self-
reported by the participants.
e) Variables of smoking cessation services reported by
the participants, such as, if used, any other strategy
for tobacco cessation, will be registered. It will also
be recorded whether the patient has actively spoken
with their psychiatrist, psychologist, nurse, or family
doctor about their participation in the quitline,
whether the professionals have agreed, and whether
they have helped them, to assess the possible
influence of these variables on the success
(or failure) of the intervention.
Collected variables and their collection frequency are
detailed in Fig. 1.
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Procedure
The research team designed a telephone-based interven-
tion with a proactive approach to help patients quit smok-
ing after discharge from hospitals. The intervention will
take into account the recommendations made by a group
of experts in the design of telephone-based interventions
(quitlines) aimed at patients with mental illnesses [39].
The intervention will also be based on the protocol of the
general quitline of 061 CatSalut Respon and a clinical
intervention guide for smoking cessation in patients with
mental disorders [28]. Depending on the case, the inter-
vention will be directed to: increase motivation to quit;
achieve abstinence; prevent relapses if achieving abstin-
ence; reduce consumption and increase motivation to quit
smoking when the patient is still not ready or motivated
to quit; and/or recommend pharmacological treatment.
The intervention will be conducted by 061 CatSalut
Respon nurses within the first 48 h, 1 week, 15 days, and
1, 3, 6, 9, and 12 months after discharge. IG subjects will
be contacted by the trained nurses and will provide an
intervention strategy adapted to each patient situation in
each call (whether they smoke, take pharmacological
treatment to quit, are ready for a quitting day calls, “D
day”, etc.) according to an algorithm procedure (Fig. 1).
The first telephone call at 48 h will serve as a starting
point for the quitline intervention outside the hospital
and to take baseline data post discharge.
CG subjects will be contacted after the first 48 h fol-
lowing discharge by nonclinical telephone assistants who
will provide brief advice (only in the first call) and col-
lect data for comparison, at this time (48 h), 1, 6, and 12
months post discharge. The investigators trained the
nonclinical telephone assistants in order to conduct the
interviews in a neutral tone following the wording of
each of the questions and not giving health recommen-
dations, as they are not qualified to do so. For patients
who express their desire to quit, telephone assistants
suggest they talk with their outpatient clinic doctor,
nurse, or psychologist to receive aid.
For those patients who met the criteria, clinicians will
invite them to participate and will deliver an informative
leaflet of the study (Additional file 1). Informed consent
will be requested within 24 h before discharge (see Fig. 2,
recruiting process). Clinicians will register participants’
data in a software program that will be used for
randomization and to transfer this information to 061
CatSalut Respon to contact the participants. All of
this baseline information is registered in the software
during the hospital stay. Finally, on the day of dis-
charge the subjects are automatically assigned ran-
domly to one of the two groups (IG or CG) by the
software. The study is blinded to prevent profes-
sionals from the hospital, and patients, from knowing
to which group they have been assigned.
Fig. 2 Recruiting process
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Telephone-based intervention components
The intervention is based on cognitive-behavioral therapy.
The intervention will include components based on
Bandura’s social learning theory, social cognitive theory
[49], and the transtheoretical model of change [43]. This
theory allows evaluating the patient motivation phase and
adapting the interventions according to each phase [27].
These components are included in the training cur-
riculum aimed at 15 nurses from 061 CatSalut Respon
who will deal with patients with mental disorders from
the IG. The specific training will include the definition
and description of the most common mental disorders,
symptoms, usual treatments, warning signs, and man-
agement, as well as the peculiarities of the smoking
cessation treatment in these patients (Table 1).
Trained nurses will help those patients to identify
their barriers and opportunities to achieve abstinence.
They will also help them to set objectives, strategies
to tackle “craving”, positive reinforcement toward pro-
gress, and increase their self-efficacy. If necessary,
nurses will recommend NRT according to the proto-
col of a clinical guideline [28], as it is a medication
that does not require medical prescription in Spain.
Nurses will have a written protocol and an algorithm
to deliver the intervention strategy according to each
patient’s situation (Fig. 3). Nurses will recommend the
patients inform their psychiatrist and/or psychologist
that they are receiving this telephone-based interven-
tion to quit smoking.
All patients in the intervention group will receive
eight telephone calls during 1 year (48 h, 1 week, 15
days, and 1 , 3 , 6 , 9, and 12 months post discharge),
regardless of whether they continue smoking or not.
The intervention lasts for 12 months, unless the pa-
tient rejects to continue participating in the study.
The intervention adapts its objectives depending on
the smoking status of the patient in each call (see
Fig. 3 in which the different strategies are explained
according to the smoking status assessed in each call,
whether he/she is abstinent or not, is willing to allo-
cate a “D day”, takes NRT).
Data collection
A computer-specific application for the study will be de-
signed for data recording and management, including
randomization. The software will be created following
the current standards of security, privacy, and confiden-
tiality. All study researchers will have access to the appli-
cation using a personal username and password.
Clinicians from each center will only be able to register
and have access to review information from patients
from their own center. The 061 CatSalut Respon nurses
will obtain data from patients registered in the five cen-
ters to do the telephone intervention. Collected data will
be exclusively used to carry out the intervention (IG or
CG), supervision, and evaluation. Patients will be in-
formed about the application uses and purposes, the ex-
istence of their profile including their personal details,
and the person responsible for their treatment, along
with their access rights, rectification, cancellation, and
opposition. Once the patient has given his/her consent,
clinicians will input data from the basal interview into
the application.
Once the study is completed, professionals from the
hospitals and 061 CatSalut Respon will no longer have
access to the database. The ICO is responsible for prop-
erly saving the files and its protection by encrypted se-
cure systems, until its eventual destruction (5 years after
study completion). The database will not identify pa-
tients in any way, creating an individual encrypted code.
Data collected during the study will be included in a file
registered by the Spanish Data Protection Agency.
The intervention and the computer application will be
firstly piloted in the five participating centers for 1
month for its evaluation before starting the study, to as-
sess the adequacy of the fieldwork circuit and make
minor changes in the protocol, if necessary.
Data analysis
The abstinence prevalence will be analyzed by groups
taking into account sociodemographic determinants.
Logistic regression analysis will be used to assess the ef-
fectiveness of the intervention (OR and 95% confidence
interval) with regard to the CG, using the different
dependent variables previously described (abstinence, re-
duction of the number of cigarettes, motivation, etc.).
Thus, the IG and the CG will be compared in different
moments of the follow-up. In addition to randomization,
to warrant comparability, we will fit multivariate logistic
models to adjust for potential confounding variables. All
analyses will be carried out by “intention to treat”, to
take into account possible losses during follow-up. We
will also analyze resource use, such as the number of
calls, satisfaction with the quitline, and type of treatment
offered, among others.
Table 1 Components of the formative curriculum
• Mental disorders, symptomatology, and general treatment
• Content, extension, and frequency of the proactive calls
• Withdrawal syndrome assessment in the mental health context
• Pharmacological recommendations about nicotine replacement
therapy
• Peculiarities of smoking cessation treatment in patients with mental
disorders, alert signs, and management
• Motivational intervention
• Communication strategies
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Fig. 3 Strategy intervention in the intervention group. NRT nicotine replacement therapy
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Ethical considerations
The intervention protocol has been approved by the Ethics
Committee for Clinical Research (CEIC) from the Bellvitge
Biomedical Research Institute (IDIBELL) (reference: PR276/
16), as well as by the Ethics Committee of each of the five
participating hospitals. The study protocol has been regis-
tered under ClinicalTrials.gov (NCT03230955, approved 24
July 2017).
At all times, requirements established by Law 14/2007,
of 3rd July, on Biomedical Research will be met by re-
searchers. The study will take place in compliance with
the Declaration of Helsinki.
Smokers who meet the inclusion criteria will receive a
brief explanation of the purpose of the study. They will
also be given an information sheet and they will be asked
to fill in the informed consent. The information will be
protected according to the standards established by
Spanish Law 15/1999 on the Protection of Personal Data.
The study termination criteria are the following (the
first to be met): conclusion of the study procedures; if a
patient explicitly states that he/she do not want to con-
tinue to participate in the study; and if a patient has re-
peatedly not been located in each of the off-tracking
visits from both the intervention or control group dur-
ing the 12months of tracking.
Discussion
Smoking has serious implications for people with severe
mental illnesses, mainly in terms of quality of life and
mortality but also in economic costs and marginalization.
Hospital mental health units are an optimal setting to
intervene and promote patient engagement in tobacco
cessation treatment [21]. For this reason, it is necessary to
offer and improve a variety of interventions to motivate
and promote cessation among these patients.
Patients with mental health disorders are usually excluded
from smoking cessation trials [20], and consequently there
is scarce evidence for the effectiveness of quitlines in this
population. As these patients usually have high comorbidity
and high smoking dependence, they represent a complex
population for smoking cessation intervention. They need
more intensive counseling, pharmacological intervention,
and longer follow-up support to achieve cessation [20], so
there is a need to tailor these strategies to this population
[50]. Only a few studies of quitline effectiveness have in-
cluded mental health patients and, usually, quitline interven-
tions have not been tailored to this population [51]. This is
the first randomized trial to test a quitline intervention
specifically tailored to the needs of mental health patients
that incorporates a long-term follow-up of 1 year, since
other studies have performed follow-up periods from 6 to 7
months [52] and with smaller samples [53].
The large sample, together with the long follow-up
period, will allow us to perform other subgroup analyses
in addition to assessing smoking cessation. The main ex-
pected outcome is an increased rate of CO-verified 7-day
point prevalence abstinence in the intervention group, as
compared with the control group. All smokers, regardless
of their level of motivation to quit, will be eligible to par-
ticipate. Analyses will consider covariates such as psychi-
atric diagnoses, use of other psychoactive substances,
psychological distress, mental illness relapse and rehospi-
talization, and sociodemographic variables. Other relevant
outcomes for comparison will include the level of motiv-
ation to quit, number of quit attempts, and level of psy-
chological distress.
There are several potential limitations. In Catalonia,
Spain, patients who have high motivation to quit
smoking at the time of discharge from acute mental
health hospitals are referred to a face-to-face intensive
smoking cessation intervention with free pharmaco-
therapy for smoking cessation. These patients are ex-
cluded from our study and, therefore, our sample
does not include patients with high motivation to quit
smoking. Nonetheless, we will assess all patients who
meet the study inclusion criteria and compare demo-
graphic, psychiatric, and tobacco use characteristics of
those who accept or decline enrollment. Another
limitation, derived from the long-term follow up de-
sign, is loss to follow-up that could bias follow-up
findings. We will perform an attrition analysis com-
paring characteristics of those followed to those not
followed at each time point. In addition, to preserve
statistical power needed to observe a 15% difference
in the quit rate between conditions, we have in-
creased the baseline sample size to accommodate an
anticipated 20% loss to follow-up at 12 months. To
increase follow-up data collection, clinicians will col-
lect contact telephone numbers for the participant
and at least two family members or caregivers. There
is potential for underreporting of smoking status at
follow-up. Participants reporting nonsmoking status at
follow-up receive a reminder and a clinic appoint-
ment to complete exhaled CO testing.
If effective, this intervention could be included in the
Catalan Health System and regularly offered to mental
health patients who smoke, no matter their motivation
to quit. We need to offer a wide range of possibilities to
intervene in smoking cessation in this population as
their smoking prevalence has not decreased in the last
decade (Additional file 2).
Additional files
Additional file 1: Informative leaflet for the quitline (DOCX 529 kb)
Additional file 2: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents (DOC 120 kb)
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